Use of octreotide for the treatment of protein-losing enteropathy in dogs: Retrospective study of 18 cases
Journal of Veterinary Internal Medicine · 2024
DOI: 10.1111/jvim.16966 ↗At a glance
Multizentrische Studie in Journal of Veterinary Internal Medicine, 2024. Written by Sara A Jablonski and 2 co-authors. Institution: Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA. Major MEDLINE topics: Protein-Losing Enteropathies, Dog Diseases, Lymphangiectasis, Intestinal. Cited 3 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
More than 50% of dogs with protein-losing enteropathy (PLE) fail to respond to standard therapies. Octreotide, a somatostatin analogue, is used in cases of intestinal lymphangiectasia (IL) in humans with some success.
Objectives
Describe the use of octreotide in dogs with PLE including reason for and details of prescription, adverse effects, and apparent response. Animals Eighteen dogs with PLE, 13 with histopathology available. Ninety-two percent (12/13) had IL diagnosed on biopsy. All 13 dogs had intestinal inflammatory infiltrates noted.
Methods
Multicenter, retrospective, descriptive study. Cases were volunteered for inclusion by individual attending veterinarians who reported the use of octreotide in cases of PLE.
Results
In 16/18 (89%) cases octreotide was prescribed to PLE dogs with a clinical suspicion or confirmed diagnosis of IL that were refractory to standard therapies. Median serum albumin at the time of octreotide prescription was 1.7 g/dL (range, 1.0-3.1 g/dL). The median dose of octreotide prescribed was 20 μg/kg, SQ, daily with a range of 4-39 μg/kg, SQ, daily. Adverse effects were noted in 3/18 (17%, 95% CI [4%, 41%]) of dogs; discontinuation of the drug was necessary in 1 dog. Improvement in clinical signs was noted in 6/12 (50%, 95% CI [21%, 79%]). Conclusions and Clinical Importance Octreotide was most commonly prescribed to dogs with PLE and suspected or confirmed IL that had failed to respond to standard therapies. Though a benefit to PLE dogs cannot be confirmed, octreotide was well tolerated by the majority of dogs at the doses prescribed in this study.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
- MI, BluePearl Veterinary Partners, Eden Prairie, Minnesota, USA.
- Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas, USA.
ORCID profiles: Sara A Jablonski, M Katherine Tolbert
Cite
APA
Jablonski, S. A., Mazepa, A. S. W., & Tolbert, M. K. (2024). Use of octreotide for the treatment of protein-losing enteropathy in dogs: Retrospective study of 18 cases. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.16966
Vancouver
Jablonski SA, Mazepa ASW, Tolbert MK. Use of octreotide for the treatment of protein-losing enteropathy in dogs: Retrospective study of 18 cases. Journal of Veterinary Internal Medicine. 2024. doi:10.1111/jvim.16966
BibTeX
@article{Jablonski2024,
author = {Jablonski, Sara A and Mazepa, Allison S W and Tolbert, M Katherine},
title = {Use of octreotide for the treatment of protein-losing enteropathy in dogs: Retrospective study of 18 cases},
journal = {Journal of Veterinary Internal Medicine},
year = {2024},
doi = {10.1111/jvim.16966}
}
EUVIMED